Volume 4.48 | Dec 13

Newsletter Issue
Prostate Cell News 4.48 December 13, 2013
Prostate Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Prostate Cell News on Twitter
 
TOP STORY
Reaction-Based Fluorescent Sensor for Investigating Mobile Zn2+ in Mitochondria of Healthy Versus Cancerous Prostate Cells
Researchers present a zinc-responsive, reaction-based, targetable probe based on the diacetyled form of Zinpyr-1. The practical utility of DA-ZP1-TPP was demonstrated by experiments revealing that, in contrast to healthy epithelial prostate cells, tumorigenic cells were unable to accumulate mobile zinc within their mitochondria. [Proc Natl Acad Sci USA] Abstract
Derivation of Metabolically Active Hepatocytes from Pluripotent Stem Cells - View On-Demand Webinar Now.
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Rb Loss Is Characteristic of Prostatic Small Cell Neuroendocrine Carcinoma
Researchers examined the status of RB1, TP53 and PTEN in prostatic small cell and acinar carcinomas via immunohistochemistry, copy number variation analysis and sequencing of formalin fixed paraffin-embedded specimens. They found Rb protein loss in 90% of small cell carcinoma cases with RB1 allelic loss in 85% of cases. [Clin Cancer Res] Abstract

ROCK Has a Crucial Role in Regulating Prostate Tumor Growth through Interaction with c-Myc
Researchers showed that inhibition of Rho-associated kinase (ROCK) activity, either by a selective ROCK inhibitor Y27632 or by specific ROCK small interfering RNA molecules, attenuated not only motility but also the proliferation of PC3 prostate cancer cells in vitro and in vivo. [Oncogene] Abstract

HOXB13 Contributes to G1/S and G2/M Checkpoint Controls in Prostate
To characterize the putative role of HOXB13 in cell cycle progression, scientists performed overexpression and siRNA-mediated knockdown studies in PC-3 and LNCaP cells. When the role of HOXB13 during cell cycle progression, association with cyclins, cell growth and colony formation using real-time cell proliferation were assessed, they observed that ectopic expression of HOXB13 accumulated cells at G1 through decreasing the cyclin D1 level by promoting its ubiquitination and degradation. [Mol Cell Endocrinol] Abstract

Activated 5’Flanking Region of NANOGP8 in a Self-Renewal Environment Is Associated with Increased Sphere Formation and Tumor Growth of Prostate Cancer Cells
Scientists evaluated the expression of NANOG1 and NANOGP8 in prostate cancer cell lines and primary cultures of prostate tissues. They investigated clonogenicity, sphere formation, and xenograft tumor growth of prostate cancer cells with an activated 5’flanking region of NANOGP8. [Prostate] Abstract

Induction of DNA Damage and p21-Dependent Senescence by Riccardin D Is a Novel Mechanism Contributing to Its Growth Suppression in Prostate Cancer Cells In Vitro and In Vivo
Scientists report that apoptosis is not the sole mechanism by which Riccardin D (RD) inhibits tumor cell growth because low concentrations of RD caused cellular senescence in prostate cancer cells. [Cancer Chemother Pharmacol] Abstract

miR-200b Suppresses Cell Proliferation, Migration and Enhances Chemosensitivity in Prostate Cancer by Regulating Bmi-1
Investigators showed that microRNA (miR)-200b was downregulated in clinical prostatic tumors when compared to normal prostate tissue and in advanced prostate cancer cell lines when compared to normal epithelial prostatic cells. [Oncol Rep] Abstract

Cells Susceptible to Epithelial-Mesenchymal Transition Are Enriched in Stem-Like Side Population Cells from Prostate Cancer
Stem-like side population cells acquired more complete epithelial-mesenchymal transition molecular features and exhibited stronger aggressive capability than homologous bulk population cells both in vitro and in vivo. [Oncol Rep] Abstract

Normoxic or Hypoxic CD44/CD41 a 2 B 1 Integrin-Positive Prostate PC3 Cell Side Fractions and Cancer Stem Cells
After 48 hours of culture under nitrogen with a resulting medium pH of 7.8, sorted hypoxic PC3 cells yielded a higher percentage and concentration/105 of cells in a doubly labeled CD44+/CD41+ side fraction compared with control cells cultured under normoxia. [Med Oncol] Abstract

CLINICAL RESEARCH

Randomized, Placebo-Controlled, Phase III Trial of Sunitinib Plus Prednisone Versus Prednisone Alone in Progressive, Metastatic, Castration-Resistant Prostate Cancer
Researchers evaluated angiogenesis-targeted sunitinib therapy in a randomized, double-blind trial of metastatic castration-resistant prostate cancer (mCRPC). The addition of sunitinib to prednisone did not improve overall survival compared with placebo in docetaxel-refractory mCRPC. [J Clin Oncol] Abstract

Baseline Prostate Inflammation Is Associated with a Reduced Risk of Prostate Cancer in Men Undergoing Repeat Prostate Biopsy: Results from the REDUCE Study
Investigators evaluated whether baseline acute and chronic prostate inflammation among men with an initial negative biopsy for prostate cancer (PCa) increased the risk of subsequent PCa detection in a clinical trial with systematic biopsies. [Cancer] Abstract

Relationship of Chronic Histologic Prostatic Inflammation in Biopsy Specimens With Serum Isoform [-2]proPSA (p2PSA), %p2PSA, and Prostate Health Index in Men with a Total Prostate-Specific Antigen of 4-10 ng/mL and Normal Digital Rectal Examination
Researchers investigated the relationship between serum [-2]proPSA (p2PSA) and derivatives with chronic histologic prostatic inflammation in men undergoing prostate biopsy for suspected prostate cancer. [Urology] Abstract

Use TeSR-E7 to generate iPS cells with high quality colony morphology for easy identification and rapid subcloning. Request your sample.
 
REVIEWS
The Prostate-Specific Membrane Antigen: Lessons and Current Clinical Implications from 20 Years of Research
Twenty years from its discovery, prostate-specific membrane antigen represents a viable biomarker and treatment target in prostate cancer. Research to delineate its precise role in prostate carcinogenesis and within the therapeutic armamentarium for patients with prostate cancer remains encouraging. [Urol Oncol] Abstract

Circulating Tumor Cells in Prostate Cancer
The authors review the main circulating tumor cells studies in advanced and localized prostate cancer, highlighting the important gains as well as the challenges posed by various approaches, and their implications for advancing prostate cancer management. [Cancers] Abstract | Full Article

Visit our reviews page to see a complete list of reviews in the prostate cell research field.
 
INDUSTRY NEWS
Rexahn Receives Method Patent for Treatment of Solid Tumor Cancers for SupinoxinTM (RX-5902)
Rexahn Pharmaceuticals, Inc. announced that it has been issued United States Patent, No. 8,598,173, which covers a method for treating solid cancer tumors including ovarian, breast, prostate, liver, lung, kidney, colon, pancreatic and stomach for its clinical development candidate SupinoxinTM (RX-5902). [Rexahn Pharmaceuticals, Inc.] Press Release

Medivation and Astellas Initiate Phase III Study of Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer
Medivation, Inc. and Astellas Pharma Inc. announced enrolment of the first patient in a global Phase III clinical trial, known as PROSPER, which will evaluate the safety and efficacy of enzalutamide in patients with non-metastatic castration-resistant prostate cancer. [Astellas Pharma Inc.] Press Release

New wallchart from our sponsor: Mesenchymal Stem Cells (a Nature Reviews Molecular Cell Biology collaboration). Request your free copy.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW International Society for Cellular Therapy 2014
April 23-26, 2014
Paris, France

Visit our events page to see a complete list of events in the prostate cell community.
 
JOB OPPORTUNITIES
NEW Postdoctoral Position – Stem Cells and Bioengineering (Queensland University of Technology/Translational Research Institute)

NEW Postdoctoral Fellow – Molecular Mechanisms of Prostate Cancer (Northwestern University- Feinberg School of Medicine)

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Postdoctoral Position – Chemistry and Prostate Cancer Imaging (University of California San Francisco)

Postdoctoral Fellow – Mechanisms Promoting Castrate Resistant Prostate Cancer (Mount Sinai School of Medicine)

Postdoctoral Fellow – Development and Progression of Prostate Cancer (University of Maryland Baltimore, School of Medicine)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Learn more about Prostate Cell News: Archives | Events | Contact Us